The interaction of gut microbes with host ABC transporters

Gut Microbes

Volumn 1, Issue 5, 2010, Pages

  Mercado Lubo, Regino ^a   McCormick, Beth A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

ABC transporters; Cystic fibrosis transmembrane regulator (CFTR); Listeria monocytogenes; Multidrug resistance associated protein 2 (MRP2); P glycoprotein; Salmonella enterica serotype typhi; Salmonella enterica serotype typhimurium; Vibrio cholerae

Indexed keywords

ABC TRANSPORTER; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; TRANSMEMBRANE CONDUCTANCE REGULATOR;

HUMAN; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; LISTERIA MONOCYTOGENES; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SINGLE NUCLEOTIDE POLYMORPHISM;

BACTERIA (MICROORGANISMS); LISTERIA MONOCYTOGENES; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHI; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; VIBRIO CHOLERAE;

EID: 77957654292     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.1.5.12925     Document Type: Review

References (56)

1. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. May 1 2005; 204:216-37.
2. Petrovic V, Teng S, Piquette-Miller M. Regulation of drug transporters during infection and inflammation. Mol Interv 2007; 7:99-111.
3. Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003; 52:1788-95.
4. Resta-Lenert S, Smitham J, Barrett KE. Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/-mice. Am J Physiol Gastrointest Liver Physiol 2005; 289:153-62.
5. Meddings JB. Review article: Intestinal permeability in Crohn's disease. Aliment Pharmacol Ther 1997; 11:47-53.
6. Boismenu R, Chen Y. Insights from mouse models of colitis. J Leukoc Biol 2000; 67:267-78.
7. Gewirtz AT, Neish AS, Madara JL. Mechanisms of active intestinal inflammation and potential downregulation via lipoxins. Adv Exp Med Biol 2002; 507:229-36.
8. Hibi T, Ogata H, Sakuraba A. Animal models of inflammatory bowel disease. J Gastroenterol 2002; 37:409-17.
9. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61:3458-64.
10. Mottino AD, Hoffman T, Jennes L, Vore M. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 2000; 293:717-23.
11. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-8.
12. Higgins CF. The ABC of channel regulation. Cell 1995; 82:693-6.
13. Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta 2000; 1486:128-44.
14. Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta 1999; 1461:347-57.
15. Dean M, Hamon Y, Chimini G. The human ATPbinding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42:1007-17.
16. Neudeck BL, Loeb JM, Faith NG, Czuprynski CJ. Intestinal P glycoprotein acts as a natural defense mechanism against Listeria monocytogenes. Infect Immun 2004; 72:3849-54.
17. Siccardi D, Mumy KL, Wall DM, Bien JD, McCormick BA. Salmonella enterica serovar Typhimurium modulates P-glycoprotein in the intestinal epithelium. Am J Physiol Gastrointest Liver Physiol 2008; 294:1392-400.
18. Schlech WF, 3rd, Lavigne PM, Bortolussi RA, et al. Epidemic listeriosis-evidence for transmission by food. N Engl J Med 1983; 308:203-6.
19. McCormick BA, Colgan SP, Delp-Archer C, Miller SI, Madara JL. Salmonella typhimurium attachment to human intestinal epithelial monolayers: transcellular signalling to subepithelial neutrophils. J Cell Biol 1993; 123:895-907.
20. Ye S, MacEachran DP, Hamilton JW, O'Toole GA, Stanton BA. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif. Am J Physiol Cell Physiol 2008; 295:807-18.
21. Lee CH. Reversing Agents for ATP-Binding Cassette Drug Transporters. Methods Mol Biol 596:325-40.
22. Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 596:341-58.
23. Saclarides TJ, Jakate SM, Coon JS, et al. Variable expression of P-glycoprotein in normal, inflamed and dysplastic areas in ulcerative colitis. Dis Colon Rectum 1992; 35:747-52.
24. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124:26-33.
25. Yacyshyn B, Maksymowych W, Bowen-Yacyshyn MB. Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis. Hum Immunol 1999; 60:677-87.
26. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161:5733-44.
27. Maggio-Price L, Shows D, Waggie K, et al. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am J Pathol 2002; 160:739-51.
28. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003; 52:759-66.
29. Blokzijl H, Vander Borght S, Bok LI, et al. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis 2007; 13:710-20.
30. Ardizzone S, Maconi G, Bianchi V, et al. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:516-23.
31. Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol 2006; 12:3636-44.
32. Potocnik U, Ferkolj I, Glavac D, Dean M. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun 2004; 5:530-9.
33. Croucher PJ, Mascheretti S, Foelsch UR, Hampe J, Schreiber S. Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent northern European populations. Gastroenterology 2003; 125:1919-20.
34. Hugot JP. Inflammatory bowel disease: a complex group of genetic disorders. Best Pract Res Clin Gastroenterol 2004; 18:451-62.
35. Van Aubel RA, Peters JG, Masereeuw R, Van Os CH, Russel FG. Multidrug resistance protein mrp2 mediates ATP-dependent transport of classic renal organic anion p-aminohippurate. Am J Physiol Renal Physiol 2000; 279:713-7.
36. Pazos M, Siccardi D, Mumy KL, et al. Multidrug resistance-associated transporter 2 regulates mucosal inflammation by facilitating the synthesis of hepoxilin A3. J Immunol 2008; 181:8044-52.
37. Mrsny RJ, Gewirtz AT, Siccardi D, et al. Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia. Proc Natl Acad Sci USA 2004; 101:7421-6.
38. Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut 1992; 33:320-3.
39. Adenis A, Colombel JF, Lecouffe P, et al. Increased pulmonary and intestinal permeability in Crohn's disease. Gut 1992; 33:678-82.
40. Trezise AE, Ratcliff R, Hawkins TE, et al. Co-ordinate regulation of the cystic fibrosis and multidrug resistance genes in cystic fibrosis knockout mice. Hum Mol Genet 1997; 6:527-37.
41. Breuer W, Slotki IN, Ausiello DA, Cabantchik IZ. Induction of multidrug resistance downregulates the expression of CFTR in colon epithelial cells. Am J Physiol 1993; 265:1711-5.
42. Trezise AE, Romano PR, Gill DR, et al. The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J 1992; 11:4291-303.
43. Welsh MJ, Anderson MP, Rich DP, et al. Cystic fibrosis transmembrane conductance regulator: a chloride channel with novel regulation. Neuron 1992; 8:821-9.
44. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999; 79:23-45.
45. Pier GB, Grout M, Zaidi T, et al. Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature 1998; 393:79-82.
46. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997; 94:12088-93.
47. Raffatellu M, Wilson RP, Winter SE, Baumler AJ. Clinical pathogenesis of typhoid fever. J Infect Dev Ctries 2008; 2:260-6.
48. House D, Bishop A, Parry C, Dougan G, Wain J. Typhoid fever: pathogenesis and disease. Curr Opin Infect Dis 2001; 14:573-8.
49. Lyczak JB, Pier GB. Salmonella enterica serovar typhi modulates cell surface expression of its receptor, the cystic fibrosis transmembrane conductance regulator, on the intestinal epithelium. Infect Immun 2002; 70:6416-23.
50. Lyczak JB. Commensal bacteria increase invasion of intestinal epithelium by Salmonella enterica serovar Typhi. Infect Immun 2003; 71:6610-4.
51. Thiagarajah JR, Verkman AS. New drug targets for cholera therapy. Trends Pharmacol Sci 2005; 26:172-5.
52. Lencer WI, Moe S, Rufo PA, Madara JL. Transcytosis of cholera toxin subunits across model human intestinal epithelia. Proc Natl Acad Sci USA 1995; 92:10094-8.
53. Lencer WI. Microbes and microbial Toxins: paradigms for microbial-mucosal toxins. V. Cholera: invasion of the intestinal epithelial barrier by a stably folded protein toxin. Am J Physiol Gastrointest Liver Physiol 2001; 280:781-6.
54. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004; 363:223-33.
55. Ma T, Thiagarajah JR, Yang H, et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002; 110:1651-8.
56. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, Verkman AS. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis and in vivo efficacy. J Gen Physiol 2004; 124:125-37.